source
- AusperBio secures $120 million Series C to push hepatitis B antisense therapy into Phase 3AusperBio Therapeutics announced it has closed a $120 million Series C financing round aimed at moving its hepatitis B antisense oligonucleotide candidate toward late‑stage trials and eventual mark…
- Cytokinetics reports positive pivotal trial results for aficamten in non-obstructive hypertrophic cardiomyopathyBiotech Cytokinetics disclosed full data from a pivotal study of its drug aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The trial met both primary endpoints, showin…STAT · 10d agoPositive readoutPositive